Cargando…
Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360699/ https://www.ncbi.nlm.nih.gov/pubmed/34391548 http://dx.doi.org/10.1016/S2213-2600(21)00366-0 |
| _version_ | 1783737795215360000 |
|---|---|
| author | Richardson, Christopher D |
| author_facet | Richardson, Christopher D |
| author_sort | Richardson, Christopher D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8360699 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83606992021-08-13 Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19 Richardson, Christopher D Lancet Respir Med Comment Elsevier Ltd. 2021-11 2021-08-13 /pmc/articles/PMC8360699/ /pubmed/34391548 http://dx.doi.org/10.1016/S2213-2600(21)00366-0 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Richardson, Christopher D Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19 |
| title | Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19 |
| title_full | Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19 |
| title_fullStr | Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19 |
| title_full_unstemmed | Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19 |
| title_short | Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19 |
| title_sort | heterologous chadox1-ncov19–bnt162b2 vaccination provides superior immunogenicity against covid-19 |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360699/ https://www.ncbi.nlm.nih.gov/pubmed/34391548 http://dx.doi.org/10.1016/S2213-2600(21)00366-0 |
| work_keys_str_mv | AT richardsonchristopherd heterologouschadox1ncov19bnt162b2vaccinationprovidessuperiorimmunogenicityagainstcovid19 |